Taysha Gene Therapies Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 5, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	1,626	1,568	355	331	141	448
Market Cap Growth	158.60%	342.19%	7.14%	134.50%	-68.52%	-55.28%
Enterprise Value	1,437	1,316	276.37	245.99	111.65	362.21
Last Close Price	5.66	5.50	1.73	1.77	2.26	11.65
PS Ratio	220.20	160.42	42.55	21.42	56.40	-
PB Ratio	7.98	6.35	4.96	4.42	148.70	4.70
P/TBV Ratio	9.18	7.12	6.05	2.74	104.67	4.60
EV/Sales Ratio	192.36	134.64	33.17	15.92	44.62	-
Debt / Equity Ratio	0.31	0.28	0.86	0.79	61.55	0.66
Net Debt / Equity Ratio	-0.99	-1.02	-1.09	-1.13	-31.06	-0.90
Net Debt / EBITDA Ratio	1.60	2.30	0.87	1.20	0.18	0.50
Net Debt / FCF Ratio	1.87	2.69	0.96	1.11	0.27	0.65
Asset Turnover	0.02	0.04	0.05	0.10	0.01	0
Quick Ratio	13.78	12.06	5.32	3.93	1.40	2.88
Current Ratio	14.04	12.23	5.42	4.08	1.54	3.08
Return on Equity (ROE)	-56.61%	-68.45%	-121.94%	-294.04%	-344.67%	-100.68%
Return on Assets (ROA)	-41.19%	-43.88%	-54.91%	-48.45%	-95.49%	-73.29%
Return on Invested Capital (ROIC)	-720.96%	-473.43%	-265.19%	-138.79%	-275.87%	-626.01%
Return on Capital Employed (ROCE)	-44.41%	-49.01%	-67.72%	-72.63%	-143.95%	-83.71%
Buyback Yield / Dilution	-32.50%	-27.82%	-115.41%	-164.20%	-16.74%	-113.13%
Total Shareholder Return	-32.50%	-27.82%	-115.41%	-164.20%	-16.74%	-113.13%

SEC Filings: 10-K · 10-Q